Insider Selling: Invivyd (NASDAQ:IVVD) Insider Sells $25,793.04 in Stock

Invivyd, Inc. (NASDAQ:IVVD) insider Jill Andersen sold 30,706 shares of the stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $0.84, for a total value of $25,793.04. Following the sale, the insider owned 283,774 shares of the company’s stock, valued at $238,370.16. This represents a 9.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jill Andersen also recently made the following trade(s):

• On Monday, August 17th, Jill Andersen sold 37,256 shares of Invivyd stock. The stock was sold at an average price of $0.72, for a total transaction of $26,824.32.

Invivyd Stock Performance

Shares of NASDAQ IVVD traded up $0.13 during mid-day trading on Tuesday, hitting $0.87. The stock had a trading volume of 7,732,095 shares, compared to its average volume of 3,061,089. Invivyd, Inc. has a 1 year low of $0.48 and a 1 year high of $3.07. The business has a 50 day moving average price of $0.77 and a two-hundred day moving average price of $1.23. The firm has a market cap of $255.75 million, a P/E ratio of -2.63 and a beta of 0.71.

Invivyd (NASDAQ:IVVD) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.03). The firm had revenue of $14.29 million for the quarter, compared to analysts’ expectations of $14.40 million. Invivyd had a negative net margin of 183.90% and a negative return on equity of 59.73%. Equities research analysts predict that Invivyd, Inc. will post -0.52 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in IVVD. Chicago Partners Investment Group LLC purchased a new position in shares of Invivyd in the 1st quarter valued at approximately $25,000. Courier Capital LLC purchased a new stake in Invivyd in the fourth quarter worth $25,000. Bronte Capital Management Pty Ltd. bought a new position in Invivyd in the fourth quarter worth $27,000. DRW Securities LLC bought a new position in Invivyd in the fourth quarter worth $27,000. Finally, ProShare Advisors LLC purchased a new position in Invivyd during the fourth quarter valued at $30,000. Institutional investors own 70.36% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on IVVD. BTIG Research reiterated a “buy” rating on shares of Invivyd in a report on Tuesday, July 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Invivyd in a report on Friday, July 24th. HC Wainwright reaffirmed a “buy” rating on shares of Invivyd in a research report on Tuesday. Finally, Wall Street Zen cut Invivyd from a “hold” rating to a “strong sell” rating in a report on Saturday, May 16th. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $8.00.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.